At Roche and Genentech, patient safety is a priority. These post-authorisation safety studies demonstrate our commitment.
Please click the icons to learn more
DMT, disease-modifying therapies; LMP, last menstrual period; OCR, ocrelizumab; pwMS, people with MS; SAEs, serious adverse events; US, United States.
M-XX-00007224 (Date of preparation: October 2021)
Link to third party site
The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.